Life Sciences Tools & Services · Nasdaq
TECHBIO-TECHNE Corp
- Last close
- $72.80 -0.1%
- 52-week range
- $43.20 to $72.88
- Market cap
- $11.4B
- Next earnings
- Not scheduled
Fiscal 2026 at a glance
Stock price
Valuation vs its own 10 years
Below its 10-year median on 3 of 4 multiples
Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.
Key statistics
Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.
Valuation
- P/E
- 67.0x
- Earnings yield
- 1.5%
- Price / sales
- 9.3x
- Price / book
- 5.3x
- Price / operating cash flow
- 33.9x
- EV / EBITDA
- 32.8x
- EV / sales
- 9.0x
- Free cash flow yield
- 2.7%
Profitability
- Gross margin
- 65.8%
- Operating margin
- 19.6%
- Net margin
- 14.0%
- Return on equity
- 7.9%
- Return on capital
- 8.4%
Growth per year
- Revenue, 3 years
- +2.2%
- Revenue, 5 years
- +5.5%
- Revenue, 9 years
- +8.9%
- EPS, 3 years
- -13.0%
Balance sheet
- Cash and investments
- $350M
- Total debt
- n/a
- Net cash
- $350M
- Debt / equity
- n/a
- Current ratio
- 2.28x
n/a: No debt reported
Shares and dividend
- Shares outstanding
- 157M
- Share count, 5 years
- -3.0%
- Beta, 1 year
- 0.64
- Dividend yield
- n/a
- Dividend per share, TTM
- n/a
- Payout ratio
- 29.1%
n/a: No dividend
Ten years of the business
Last 40 quarters, fiscal 2017 to 2026 and after. Hover a bar for its quarter.
Fiscal years 2017 to 2026.
Where the revenue comes from
Instruments went from 10% to 9% of revenue in 3 years
Share of revenue by product line, fiscal 2023 to 2026, as reported in the 10-K.
| Product line | Revenue | Share | vs FY25 |
|---|---|---|---|
| Consumables | $985M | 81.1% | +1% |
| Instruments | $111M | 9.1% | -1% |
| Services | $94.3M | 7.8% | -15% |
| Royalty | $25.0M | 2.1% | +5% |
Life Sciences Tools & Services peers
The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.
| Company | Market cap | Revenue growth | Operating margin | P/E | P/S | P/E vs own history |
|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc. | $259B | +8% | 17.9% | 36.9x | 5.5x | 88th percentile |
| A Agilent Technologies, Inc. | $49.0B | +9% | 22.2% | 34.2x | 6.7x | 64th percentile |
| WAT Waters Corp | $45.2B | +81% | 4.7% | 198x | 8.1x | 90th percentile |
| IQV Iqvia Holdings Inc. | $43.7B | +9% | 12.8% | 32.2x | 2.5x | 38th percentile |
| MTD Mettler Toledo International Inc/ | $34.6B | +7% | n/a | 37.7x | 8.2x | 58th percentile |
| TECH BIO-TECHNE Corp | $11.4B | +1% | 19.6% | 67.0x | 9.3x | 60th percentile |
The company
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Headquarters
- Minneapolis, MN
- Fiscal year ends
- June
Around the numbers
What the rest of EdgeStacker knows about TECH.